CONTINUING EDUCATION (CE) LANGUAGE

Title:                   Evaluation and Management of a Post-Surgical Patient with Hirschsprung Disease: It Takes a Village and Intricate Teamwork

Date:                   July 29, 2026

Location:             Online

ACCME Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). NASPGHAN is accredited by the ACCME to provide continuing medical education for physicians.

ACCME provider number: 0005000

Credit Designation Statement

NASPGHAN designates this live activity for a maximum of 1 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

ABP MOC Part 2 Credits

Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn up to 1 MOC Part 2 points for the live webinar in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

Participant must complete the assessment within 30 days of the activity.

Juvenile Polyposis Syndrome (JPS) is a rare, inherited gastrointestinal polyposis syndrome with significant variability in clinical presentation and associated risks. As research continues to identify important genotype–phenotype correlations, a more personalized approach to surveillance and management is emerging.

Join us for From Genes to Guidelines to Bedside: Personalized Management of Pediatric Juvenile Polyposis Syndrome, a webinar examining how evolving evidence can inform the care of children with JPS.

Experts will explore the distinction between sporadic and syndromic juvenile polyps, foundational guidelines for JPS management, genotype-specific surveillance considerations, and evolving approaches to polypectomy and chemoprevention.